Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Proprietary drug

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Proprietary drug. Displaying page 1 of 1.
    EudraCT Number: 2021-001637-39 Sponsor Protocol Number: RP630601 Start Date*: 2021-06-02
    Sponsor Name:Repare Therapeutics
    Full Title: Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination with RP-3500 in Patients with Advanced Solid Tumors
    Medical condition: Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002672-13 Sponsor Protocol Number: RH/BARACKD/0003 Start Date*: 2013-04-09
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance Office
    Full Title: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial: a prospective randomised open blinded endpoint trial to determine the effect of aldosterone receptor antagoni...
    Medical condition: We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate marke...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    15.1 10022891 - Investigations 10018355 Glomerular filtration rate PT
    15.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-006044-14 Sponsor Protocol Number: EB05-04-2020 Start Date*: 2021-10-25
    Sponsor Name:Edesa Biotech Research Inc.
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + SOC vs. placebo + SOC in adult hospitalized patients with COVID19
    Medical condition: SARS-CoV-2 Positive Pneumonia - level 3-7 in the nine-point COVID-19 severity scale:
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    23.1 10021881 - Infections and infestations 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013638-26 Sponsor Protocol Number: UCL/08/0359 Start Date*: 2011-08-24
    Sponsor Name:University College London
    Full Title: A phase I/II study of first line Vorinostat with pemetrexed-cisplatin, in patients with malignant pleural mesothelioma
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002854-21 Sponsor Protocol Number: CNVA237A2311 Start Date*: 2013-02-19
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/fluticasone p...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000977-29 Sponsor Protocol Number: EMA401-003 Start Date*: 2011-07-12
    Sponsor Name:Spinifex Pharmaceuticals Pty Ltd
    Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor...
    Medical condition: postherpetic neuralgia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002709-23 Sponsor Protocol Number: PLN-74809-IPF-202 Start Date*: 2020-11-06
    Sponsor Name:Pliant Therapeutics Inc.
    Full Title: A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IP...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:17:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA